For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 32,672 | |||
| General and administrative | 23,713 | |||
| Total operating expenses | 56,385 | |||
| Net operating loss | -56,385 | |||
| Interest income | 3,819 | |||
| Interest expense | 0 | |||
| Other (expense) income, net | -33 | |||
| Net loss | -52,599 | |||
| Basic EPS | -1.34 | |||
| Diluted EPS | -1.34 | |||
| Basic Average Shares | 39,217,244 | |||
| Diluted Average Shares | 39,217,244 | |||
TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC. (TENX)